Asparkam

General characteristics. Structure:

Active ingredients: 1 tablet contains magnesium of asparaginate 175 mg (0,175 g), potassium of asparaginate of 175 mg (0,175 g);

excipients: starch corn, polysorbate-80, calcium stearate, talc.

Description. Tablets of white color, with a smooth surface, ploskotsilindrichesky, with risky, with a specific smell. On a surface of tablets the mramornost is allowed.

Pharmacological properties:

The asparkam belongs to the medicines regulating metabolic processes. The mechanism of action is connected with a role of asparaginat to transfer ions of magnesium and potassium to intracellular space and their participation in metabolic processes. The asparkam eliminates an imbalance of electrolytes, deficit of magnesium and potassium, lowers excitability and conductivity of a myocardium, shows moderate antiarrhytmic effect, improves a metabolism in a myocardium and coronary circulation, and also reduces sensitivity of a myocardium to cardiac glycosides and manifestations of their toxicity. Mg2 ions + activate Na+, To +-Atfazy. In this connection intracellular concentration of ions of Na+ decreases and receipt of ions of K+ in cells increases. At decrease in concentration of ions of Na + in a cell there is a braking of exchange of ions of Na + and Sa2+ in unstriated muscles of vessels that leads to their relaxation. Ions stimulate with K+ synthesis of ATP, a glycogen, proteins, acetylcholine. Ions by K+ and Mg2+ support polarization of cellular membranes. Asparaginate is the carrier of ions of K+ and Mg2+ and promotes their receipt in intracellular space. Getting to a cell, asparaginate also joins in metabolism processes, promotes synthesis of amino acids, aminosugars, nucleotides, nitrogen-containing lipids, adjusts disturbance of energy balance of an ischemic myocardium.

It is quickly and completely soaked up, removed preferential by kidneys. Potassium concentration and magnesium in blood reaches a maximum in 1-2 hours after administration of drug. From blood drug gets in cardiomyocytes in the form of ions of K+, Mg2+, and asparaginate and joins in cellular metabolism.

Indications to use:

As a part of complex therapy of heart failure, a state after a myocardial infarction, disturbances of a cordial rhythm (preferential ventricular arrhythmias) caused by electrolytic disturbances;
for strengthening of efficiency and improvement of portability of cardiac glycosides;
at the states which are followed by a hypopotassemia and a hypomagnesiemia (including overdose of saluretics).

Route of administration and doses:

The asparkam, tablets, accept orally.

The adult drug is appointed on 1-2 tablets by 3 times a day after food.

The course of treatment is defined by the doctor depending on character and the course of a disease.

Side effects:

Side reactions develop very seldom:
from a digestive tract: nausea, vomiting, diarrhea, an abdominal pain, a sensation of discomfort or burnings in epigastric area, gastrointestinal bleedings, ulcers of a mucous membrane of a digestive tract, dryness in a mouth;
from cardiovascular system: disturbance of conductivity of a myocardium, lowering of arterial pressure, AV-blockade;
from the central and peripheral nervous system: paresthesias, hyporeflexia, spasms;
allergic reactions: itch, erubescence of the person, rash;
from respiratory system: respiratory depression is possible (it is caused by a gipermagniyemiya);
others: feeling of heat.

Interaction with other medicines:

Due to the existence in composition of drug of potassium ions at use of the Asparkam with kaliysberegayushchy diuretics, APF inhibitors, beta adrenoblockers, cyclosporine the risk of development of a hyperpotassemia (control of level of potassium in a blood plasma is necessary) increases and the oppressing influence on an intestines peristaltics amplifies.

Drug slows down absorption of peroral forms of tetracycline, salts of iron and sodium fluoride (it is necessary to adhere to a three-hour interval between receptions).

The asparkam strengthens effect of medicines which stimulate trophic processes in a myocardium; prevents development of the hypopotassemia caused by use of saluretics, corticosteroids, cardiac glycosides. The asparkam reduces cardiotoxic effect of cardiac glycosides.

At simultaneous use with the anti-depolarizing muscle relaxants neuromuscular blockade amplifies, with anesthetics (Ketaminum, geksanat, Ftorotanum, etc.) – the central nervous system is oppressed.

The asparkam can reduce efficiency of Neomycinum, polymyxin B, tetracycline and streptomycin.

Contraindications:

Hypersensitivity to drug components;
acute and chronic renal failure;
Addison's disease;
hyperpotassemia, gipermagniyemiya;
atrioventricular block of II-Iiistepeni;
cardiogenic shock (ABP <90 mm Hg).

Appropriate security measures at use. At long use of drug it is necessary to control the level of potassium and magnesium in blood, and also regular monitoring of indicators of an electrolytic hemostasis and data of an ECG is necessary.

Use during pregnancy or feeding by a breast. Data on a negative impact of drug during pregnancy or feeding by a breast are absent. Use of drug is possible if, according to the doctor, the expected advantage for mother exceeds risk for a fruit or the child.

Ability to influence speed of response at control of motor transport or work with other mechanisms. The asparkam does not influence speed of response at control of motor transport or work with other mechanisms. 

Children. Children do not have experience of use of drug.

Overdose:

At the moment cases of overdose are not registered. Theoretically at overdose hyperpotassemia symptoms (nausea, vomiting, diarrhea, an abdominal pain, metal smack in a mouth, bradycardia, weakness, a disorientation, muscular paralysis, paresthesias of extremities) and gipermagniyemiya (erubescence of the person, thirst, arterial hypotension, a hyporeflexia, neuromuscular transmission disturbance, respiratory depression, arrhythmia, spasms) can develop. On the electrocardiogram increase in height of a tooth of T, decrease in amplitude of a tooth P, expansion of the QRS complex is registered.
 
Treatment: drug withdrawal, symptomatic therapy (intravenous administration of solution of Calcii chloridum in a dose on 100 mg/min.), if necessary – a hemodialysis.

Storage conditions:

Period of validity 3 years. To store in the dry place at a temperature not above 25 °C. To store in the place, unavailable to children.

Issue conditions:

Without recipe

Packaging:

On 50 tablets in the blister; on 50 tablets in the blister, 1 blister in a pack.